1-20 of 22
Richard B. Lanman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors

Neelima Vidula, Thereasa A. Rich, Oliver Sartor, Jennifer Yen, Aaron Hardin, Tracy Nance, Michael B. Lilly, Mohammad Amin Nezami, Sandip P. Patel, Benedito A. Carneiro, Alice C. Fan, Adam M. Brufsky, Barbara A. Parker, Benjamin B. Bridges, Neeraj Agarwal, Benjamin L. Maughan, Victoria M. Raymond, Stephen R. Fairclough, Richard B. Lanman, Aditya Bardia, Massimo Cristofanilli
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2546–2555.
https://doi.org/10.1158/1078-0432.CCR-19-2933
Published: 01 June 2020
View articletitled, Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
Open the PDF for Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress

Jason Agulnik, Jennifer H. Law, Rosalyn Juergens, Janessa Laskin, Scott Laurie, Desiree Hao, Doreen A. Ezeife, Lisa W. Le, Lesli A. Kiedrowski, Richard B. Lanman, Natasha B. Leighl
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A26.
https://doi.org/10.1158/1557-3265.LiqBiop20-A26
Published: 01 June 2020
View articletitled, Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress
Journal Articles

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Seyed Pairawan, Kenneth R. Hess, Filip Janku, Nora S. Sanchez, Kenna R. Mills Shaw, Cathy Eng, Senthilkumar Damodaran, Milind Javle, Ahmed O. Kaseb, David S. Hong, Vivek Subbiah, Siqing Fu, David R. Fogelman, Victoria M. Raymond, Richard B. Lanman, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1924–1931.
https://doi.org/10.1158/1078-0432.CCR-19-0306
Published: 15 April 2020
View articletitled, Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer
Open the PDF for Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer in another window
Includes: Supplementary data
Journal Articles

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Julia K. Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwei Yeh, Boris C. Bastian, Petr Starostik, Kimberly Newsom, Victor R. Olivas, Alexander M. Wolff, James S. Fraser, Eric A. Collisson, Caroline E. McCoach, D. Ross Camidge, Jose Pacheco, Lyudmila Bazhenova, Tianhong Li, Trever G. Bivona, Collin M. Blakely
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (2): 439–449.
https://doi.org/10.1158/1078-0432.CCR-19-1667
Published: 15 January 2020
View articletitled, Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Open the PDF for Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, Stacie Landron, Julie Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, Daniel V.T. Catenacci
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 7098–7112.
https://doi.org/10.1158/1078-0432.CCR-19-1704
Published: 02 December 2019
View articletitled, Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Open the PDF for Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Jason Willis, Martina I. Lefterova, Alexander Artyomenko, Pashtoon Murtaza Kasi, Yoshiaki Nakamura, Kabir Mody, Daniel V.T. Catenacci, Marwan Fakih, Catalin Barbacioru, Jing Zhao, Marcin Sikora, Stephen R. Fairclough, Hyuk Lee, Kyoung-Mee Kim, Seung Tae Kim, Jinchul Kim, Danielle Gavino, Manuel Benavides, Nir Peled, Timmy Nguyen, Mike Cusnir, Ramez N. Eskander, Georges Azzi, Takayuki Yoshino, Kimberly C. Banks, Victoria M. Raymond, Richard B. Lanman, Darya I. Chudova, AmirAli Talasaz, Scott Kopetz, Jeeyun Lee, Justin I. Odegaard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 7035–7045.
https://doi.org/10.1158/1078-0432.CCR-19-1324
Published: 02 December 2019
View articletitled, Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Open the PDF for Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel in another window
Includes: Supplementary data
Journal Articles

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6662–6670.
https://doi.org/10.1158/1078-0432.CCR-19-1436
Published: 15 November 2019
View articletitled, Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Open the PDF for Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations

Siddhartha Devarakonda, Sumithra Sankararaman, Brett H. Herzog, Kathryn A. Gold, Saiama N. Waqar, Jeffrey P. Ward, Victoria M. Raymond, Richard B. Lanman, Aadel A. Chaudhuri, Taofeek K. Owonikoko, Bob T. Li, John T. Poirier, Charles M. Rudin, Ramaswamy Govindan, Daniel Morgensztern
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6119–6126.
https://doi.org/10.1158/1078-0432.CCR-19-0879
Published: 15 October 2019
View articletitled, Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Open the PDF for Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Ahmed O. Kaseb, Nora S. Sánchez, Shiraj Sen, Robin K. Kelley, Benjamin Tan, Andrea G. Bocobo, Kian H. Lim, Reham Abdel-Wahab, Marc Uemura, Roberto Carmagnani Pestana, Wei Qiao, Lianchun Xiao, Jeffrey Morris, Hesham M. Amin, Manal M. Hassan, Asif Rashid, Kimberly C. Banks, Richard B. Lanman, AmirAli Talasaz, Kenna R. Mills-Shaw, Bhawana George, Abedul Haque, Kanwal P.S. Raghav, Robert A. Wolff, James C. Yao, Funda Meric-Bernstam, Sadakatsu Ikeda, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6107–6118.
https://doi.org/10.1158/1078-0432.CCR-18-3341
Published: 15 October 2019
View articletitled, Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Open the PDF for Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA in another window
Includes: Supplementary data
Journal Articles

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Thereasa A. Rich, Karen L. Reckamp, Young Kwang Chae, Robert C. Doebele, Wade T. Iams, Michael Oh, Victoria M. Raymond, Richard B. Lanman, Jonathan W. Riess, Thomas E. Stinchcombe, Vivek Subbiah, David R. Trevarthen, Stephen Fairclough, Jennifer Yen, Oliver Gautschi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (19): 5832–5842.
https://doi.org/10.1158/1078-0432.CCR-18-4049
Published: 01 October 2019
View articletitled, Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
Open the PDF for Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin I. Odegaard, Richard B. Lanman, Vassiliki A. Papadimitrakopoulou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (15): 4691–4700.
https://doi.org/10.1158/1078-0432.CCR-19-0624
Published: 01 August 2019
View articletitled, Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Open the PDF for Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer

Giulia Siravegna, Andrea Sartore-Bianchi, Rebecca J. Nagy, Kanwal Raghav, Justin I. Odegaard, Richard B. Lanman, Livio Trusolino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (10): 3046–3053.
https://doi.org/10.1158/1078-0432.CCR-18-3389
Published: 15 May 2019
View articletitled, Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Open the PDF for Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. Gonzalez-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric H. Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Jr, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 277–289.
https://doi.org/10.1158/1078-0432.CCR-18-1544
Published: 03 January 2019
View articletitled, Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Open the PDF for Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer

Magda Bahcall, Mark M. Awad, Lynette M. Sholl, Frederick H. Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia C. Leonardi, Bryan C. Ulrich, Cloud P. Paweletz, Paul T. Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J. Nagy, Richard B. Lanman, Marzia Capelletti, Emily S. Chambers, Amanda J. Redig, Paul A. VanderLaan, Daniel B. Costa, Yu Imamura, Pasi A. Jänne
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5963–5976.
https://doi.org/10.1158/1078-0432.CCR-18-0876
Published: 03 December 2018
View articletitled, Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Open the PDF for Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients

Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, Stefanie A. Mortimer, James V. Vowles, Reza Mokhtari, David R. Gandara, Philip C. Mack, Justin I. Odegaard, Rebecca J. Nagy, Arthur M. Baca, Helmy Eltoukhy, Darya I. Chudova, Richard B. Lanman, AmirAli Talasaz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3528–3538.
https://doi.org/10.1158/1078-0432.CCR-17-3837
Published: 31 July 2018
View articletitled, The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Open the PDF for The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, James V. Vowles, Bryan C. Ulrich, Kimberly C. Banks, Stephen R. Fairclough, Oliver A. Zill, Marcin Sikora, Reza Mokhtari, Diana Abdueva, Rebecca J. Nagy, Christine E. Lee, Lesli A. Kiedrowski, Cloud P. Paweletz, Helmy Eltoukhy, Richard B. Lanman, Darya I. Chudova, AmirAli Talasaz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (15): 3539–3549.
https://doi.org/10.1158/1078-0432.CCR-17-3831
Published: 31 July 2018
View articletitled, Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Open the PDF for Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies in another window
Includes: Supplementary data
Journal Articles

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Benedito A. Carneiro, Sahithi Pamarthy, Ami N. Shah, Vinay Sagar, Kenji Unno, HuiYing Han, Ximing J. Yang, Rubens B. Costa, Rebecca J. Nagy, Richard B. Lanman, Timothy M. Kuzel, Jeffrey S. Ross, Laurie Gay, Julia A. Elvin, Siraj M. Ali, Massimo Cristofanilli, Young K. Chae, Francis J. Giles, Sarki A. Abdulkadir
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-18-0332
Published: 14 June 2018
View articletitled, Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
Open the PDF for Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Caroline E. McCoach, Collin M. Blakely, Kimberly C. Banks, Benjamin Levy, Ben M. Chue, Victoria M. Raymond, Anh T. Le, Christine E. Lee, Joseph Diaz, Saiama N. Waqar, William T. Purcell, Dara L. Aisner, Kurtis D. Davies, Richard B. Lanman, Alice T. Shaw, Robert C. Doebele
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2758–2770.
https://doi.org/10.1158/1078-0432.CCR-17-2588
Published: 14 June 2018
View articletitled, Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
Open the PDF for Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, Ruthia Chen, Jennifer Heng, Nora Feeney, Rebecca J. Nagy, Jayshree Shah, Bryan Ulrich, Martin Gutierrez, Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7351–7359.
https://doi.org/10.1158/1078-0432.CCR-17-1745
Published: 30 November 2017
View articletitled, Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Open the PDF for Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David Briere, Jill Hallin, Pedro P. Lopez-Casas, Natalia Baños, Camino Menendez, Manuel Hidalgo, Vanessa Tassell, Richard Chao, Darya I. Chudova, Richard B. Lanman, Peter Olson, Lyudmilla Bazhenova, Sandip Pravin Patel, Carrie Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, James G. Christensen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6661–6672.
https://doi.org/10.1158/1078-0432.CCR-17-1192
Published: 31 October 2017
View articletitled, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Open the PDF for Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models in another window
Includes: Supplementary data